Elpro International Ltd.

17th Floor, Nirmal, Nariman Point Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000 F +91 22 2202 7995

CIN: L51505MH1962PLC012425

October 30, 2024

To. **BSE** Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001

Dear Sir / Ma'am,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Elpro International Limited ("the Company") has acquired Equity Shares of Sagility India Limited.

The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations, is attached as "Annexure A".

This is for your information and record.

Thanking you,

For Elpro International Limited

Digitally signed by Mohit **Mohit Premchand** Premchand Dubey

Date: 2024.10.30 Dubey 22:32:59 +05'30'

Mohit Premchand Dubey

Company Secretary and Compliance Officer ICSI Membership Number: - ACS67363

Encl. as above

Elpro International Ltd.

17th Floor, Nirmal, Nariman Point Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000 F +91 22 2202 7995

CIN: L51505MH1962PLC012425

Annexure A

Sr. No.	Particulars	Details			
1.	Name of the target entity, details in brief such as size, turnover etc.:	Sagility India Limited			
		Consolidated Turnover as per last audited financials (FY 2023-24):			
		ParticularsAmount (Rs. in Millions)Revenue from Operations47,535.57Other Income279.47Total47,815.04			
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length":	No			
3.	Industry to which the entity being acquired belongs:	Healthcare Industry			
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	Investment Purpose			
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	N.A.			
6.	Indicative time period for completion of the acquisition:	N.A.			
7.	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash consideration			
8.	Cost of acquisition or the price at which the shares are acquired:	INR 10.00 Crores			

Elpro International Ltd.

17th Floor, Nirmal, Nariman Point Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000 F +91 22 2202 7995

CIN: L51505MH1962PLC012425

India, Philippines, U.S., Jamaica and Colombia

9.	Percentage of shareholding / control acquired	Fresh Acquisit	esh Acquisition: 33,33,333 Equity Shares			
	and/or number of shares acquired:	(7)				
		(Previous Holding: Nil)				
		(Total Holding with Fresh Acquisition: 33,33,333 Equity				
1.0		Shares)				
10.	Brief background about the entity acquired in	Brief Background:				
	terms of products/line of business acquired,	Sagility is a technology-enabled, pure-play healthcare focused				
	date of incorporation, history of last 3 years	solutions and services provider that supports US-based payers, providers, and their partners to deliver best-in-class operations.				
	turnover, country in which the acquired entity has presence and any other significant					
	information (in brief):	enhance the member and provider experience, and improve the quality of care all while delivering cost effective healthcare				
	information (in orier).	financial and clinical outcomes.				
		imanetal and enineal outcomes.				
		Line of Business:				
		Healthcare Industry				
		•				
		Website of the Entity:				
		www.sagilityhealth.com/				
		D				
		Date of Incorporation: July 28, 2021				
		Consolidated Turnover of last 3 Financial Years:				
		Compositioned 1 di novel of muse of 1 municini 1 edits.				
		Particulars Amount (Rs. in Millions)		ions)		
			FY 2023-24	FY 2022-23	FY 2021-22	
		Revenue	47,535.57	42,184.08	9,234.07	
		from				
		Operations				
		Other	279.47	176.52	209.87	
		Income				
		Total	47,815.04	42,360.60	9,443.94	